Published Date: 17 Feb 2023
BACKGROUND: NSCLC is the most common and important cause of cancer worldwide. Assessment: The patient...
Read Full NewsIn a pilot study — the first to test CAR-T therapy in smoldering multiple myeloma — patients with high-risk disease remained MRD-negative for more than 15 months. But is it a cure?
New research shows how certain orphan noncoding RNA — oncRNA — can be predictable enough to be a ‘bar code’ identifying specific cancers. Liquid biopsy could be next.
A phase 3 study investigates the outcomes associated with intensive chemotherapy with or without dasatinib in core-binding factor acute myeloid leukemia.
A single-arm study hints at an uptick in pathologic complete responses when a CD39 blocker is added to perioperative durvalumab and chemotherapy for NSCLC.
A study of a real-world population underscores measurable residual disease thresholds indicative of the risk for relapse in NPM1-mutated AML, suggesting guidance in treatment decisions.
1.
'Sleep ALL night' program helps children with leukemia sleep better during treatment
2.
For the creation of cutting-edge targeted radionuclide therapies in oncology, Bayer and Bicycle Therapeutics work together.
3.
Promising OS at 5 Years With Chemo-Free Combo in Urothelial Cancer
4.
Pharyngoesophageal junction cancer is not a good candidate for endoscopically assisted transoral surgery.
5.
EU Adds CAR-T Warning; New Blincyto Indication; Good News in Pancreatic Cancer
1.
Ticagrelor Monotherapy vs. Ticagrelor + Aspirin in ACS Post-PCI: ULTIMATE-DAPT Trial
2.
Understanding Iron Saturation Levels in Your Blood
3.
Oncology Partnerships: Driving Innovation Through Strategic Collaborations and Pharma Engagement USA
4.
The Benefits and Risks of Cervical Conization
5.
Unlocking the Mysteries of ICD 10 Code Normocytic Anemia
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part IV
2.
An In-Depth Look At The Signs And Symptoms Of Lymphoma
3.
Effect of Pablociclib in Endocrine Resistant Patients - A Panel Discussion
4.
"Lorlatinib Upfront": A Niche but Powerful Option For ALK+ NSCLC
5.
An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- Panel Discussion
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation